Ana M Anderson

US Patent:

20110059106, Mar 10, 2011

Filed:

Jan 29, 2009

Appl. No.:

12/865322

Inventors:

Vijay K. Kuchroo - Newton MA, US
Ana Carrizosa Anderson - Brookline MA, US
Valerie Dardalhon - Montpellier, FR

Assignee:

BRIGHAM AND WOMEN'S HOSPITAL, INC. - Boston MA

International Classification:

A61K 39/395
A61K 38/17
A61P 37/06
A61P 35/00

US Classification:

4241581, 514 209

Abstract:

The invention provides for methods of modulating a population of myeloid-derived suppressor cells (MDSCs) in a subject, for treating an autoimmune disease, and also treating cancer in a subject in need thereof. The methods comprise administering to the subject a therapeutically effective amount of an agent that modulates the Tim-3 pathway. The Tim-3 pathway can be activated by a Tim-3 ligand, galectin-9, whereby MDSCs are expanded, or inhibited by an antibody to Tim-3, wherein the expansion of MDSCs is inhibited.

US Patent:

20130156774, Jun 20, 2013

Filed:

Jun 16, 2011

Appl. No.:

13/805030

Inventors:

Vijay K. Kuchroo - Newton MA, US
Ana C. Anderson - Brookline MA, US

Assignee:

THE BRIGHAM AND WOMEN'S HOSPITAL, INC. - Boston MA

International Classification:

C07K 16/28

US Classification:

4241361, 5303873

Abstract:

Described herein are novel compositions comprising bispecific and multispecific polypeptide agents, and methods using these agents for targeting cells, such as functionally exhausted or unresponsive immune cells, that co-express the inhibitory receptors PD-1 and TIM-3. These compositions and methods are useful for the treatment of chronic immune conditions, such as persistent infections or cancer.

US Patent:

20100061992, Mar 11, 2010

Filed:

Nov 15, 2007

Appl. No.:

12/514602

Inventors:

David E. Anderson - Brookline MA, US
Ana C. Anderson - Brookline MA, US
Vijay K. Kuchroo - Newton MA, US
David A. Hafler - Boston MA, US

Assignee:

THE BRIGHAM AND WOMEN'S HOSPITAL, INC. - Boston MA

International Classification:

A61K 39/395
A61K 38/17
A61K 48/00
A61P 37/00
A61K 39/00
A61P 35/00

US Classification:

4241391, 4241301, 514 12, 514 44 R, 4241841

Abstract:

The invention provides novel methods of treating neurological disorders, including neurodegenerative disorders such as MS. The invention also provides novel methods of treating cancers, including glial tumors such as glioblastoma multiforme. The invention further provides vaccines and related uses.

US Patent:

20210332130, Oct 28, 2021

Filed:

Feb 2, 2021

Appl. No.:

17/165120

Inventors:

- Boston MA, US
Ana C. ANDERSON - Newton MA, US

Assignee:

The Brigham and Women's Hospital, Inc. - Boston MA

International Classification:

C07K 16/28

Abstract:

Described herein are novel compositions comprising bispecific and multispecific polypeptide agents, and methods using these agents for targeting cells, such as functionally exhausted or unresponsive immune cells, that co-express the inhibitory receptors PD-1 and TIM-3. These compositions and methods are useful for the treatment of chronic immune conditions, such as persistent infections or cancer.

US Patent:

20210102168, Apr 8, 2021

Filed:

Oct 5, 2020

Appl. No.:

17/063604

Inventors:

- Boston MA, US
- Cambridge MA, US
Ana Carrizosa Anderson - Boston MA, US
Vijay K. Kuchroo - Boston MA, US
Linglin Huang - Boston MA, US

International Classification:

C12N 5/0783
C07K 16/28
C07K 16/22
C07K 16/38
C07K 16/18
C07K 16/40
A61K 39/395
A61K 35/17
C12Q 1/6886

Abstract:

The present invention is generally directed to identify interacting cells in the tumor microenvironment and using the identified interactions to enhance anti-tumor immunity in cancer. Identified interactions can be modulated using therapeutic agents. Immune cells resistant to suppression can be used for adoptive cell transfer. The present invention is also generally directed to cell types and genes that are correlated to time of tumor growth and tumor size.

US Patent:

20200095284, Mar 26, 2020

Filed:

Nov 6, 2019

Appl. No.:

16/676036

Inventors:

- BOSTON MA, US
VIJAY K. KUCHROO - NEWTON MA, US
YU-HWA HUANG - BOSTON MA, US
CHEN ZHU - BROOKLINE MA, US
ANA C. ANDERSON - BROOKLINE MA, US

Assignee:

THE BRIGHAM AND WOMEN'S HOSPITAL, INC. - BOSTON MA

International Classification:

C07K 7/08
C07K 14/705
A61K 39/395
A61K 38/10
C07K 16/30
C07K 16/28

Abstract:

Described herein are compositions and methods for the modulation of T-cell tolerance, which can be upregulated or down regulated by concurrent enhancement or inhibition of CEACAM1/TIM3 interactions. As described herein, the discovery that CEACAM1 is a direct ligand of TIM3 and vice versa has been shown in cis and in trans. In addition, as demonstrated herein, CEACAM1 and TIM3 are co-regulated during the course of T-cell activation.

US Patent:

20190040154, Feb 7, 2019

Filed:

Oct 2, 2018

Appl. No.:

16/149589

Inventors:

- Boston MA, US
Nicole Joller - Zurich, CH
Ana C. Anderson - Brookline MA, US
Patrick Burkett - Cambridge MA, US

Assignee:

THE BRIGHAM AND WOMEN'S HOSPITAL, INC. - Boston MA

International Classification:

C07K 16/42
A61K 39/395
C12Q 1/6883
G01N 33/574

Abstract:

Described herein are methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring based on the level of TIGIT, Flg2 and/or IL-33 expression and/or activity. In some embodiments, the methods and compositions described herein are directed to treatment and/or therapy monitoring of cancer and/or infections (e.g., chronic viral infection, intracellular and/or extracellular bacterial infection, and/or fungal infection). In some embodiments, the methods and compositions described herein are directed to treatment and/or therapy monitoring of autoimmune diseases and/or inflammation (e.g., caused by parasitic infection). In some embodiments, the methods and compositions described herein are directed to treatment and/or therapy monitoring of asthma, allergy, and/or atopy. Methods for identifying patients who are more likely to be responsive to and benefit from an immunotherapy that targets TIGIT, Fg12 and/or IL-33 are also described herein.

US Patent:

20180051083, Feb 22, 2018

Filed:

Nov 3, 2017

Appl. No.:

15/803079

Inventors:

- Boston MA, US
Ana C. ANDERSON - Newton MA, US

Assignee:

The Brigham and Women's Hospital, Inc. - Boston MA

International Classification:

C07K 16/28
A61K 39/00

Abstract:

Described herein are novel compositions comprising bispecific and multispecific polypeptide agents, and methods using these agents for targeting cells, such as functionally exhausted or unresponsive immune cells, that co-express the inhibitory receptors PD-1 and TIM-3. These compositions and methods are useful for the treatment of chronic immune conditions, such as persistent infections or cancer.